Program
Chickenpox Vaccine
Also written as “Varicella Vaccine”, “Investigational live attenuated varicella vaccine” and “Zoster Vaccine, Live”.
Its studies are mostly in Chickenpox · Herpes Zoster · Meningococcal Infections · Measles · Streptococcal Infections, led by 6 companies.
Drug pageChickenpox Vaccine: every studyMany companies study it; this page follows only the 43 they lead. All 76 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merckits history only | 210 open or running | phase 4since Feb 7, 2007 | Apr 22, 2005 | none ahead |
| Sinovac Biotechits history only | 124 open or running | phase 4since Oct 14, 2021 | Nov 14, 2016 | Dec 2028phase 4 · NCT06484686 |
| GlaxoSmithKlineits history only | 60 open or running | phase 3since Sep 13, 2005 | Sep 13, 2005 | none ahead |
| Sinopharmits history only | 22 open or running | phase 3since Dec 20, 2022 | Dec 20, 2022 | none ahead |
| Changchun Changsheng Life Science and Technologyits history only | 10 open or running | phase 4since Oct 24, 2013 | Oct 24, 2013 | none ahead |
| GC Biopharmaits history only | 10 open or running | phase 3since Nov 28, 2017 | Nov 28, 2017 | none ahead |
Also a collaborator on its studies: Beijing Institute of Biological Products.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 27 studies since Apr 22, 2005.
- Nov 14, 2016Sinovac Biotech’s first study: phase 1 study in ChickenpoxNew to Sinovac BiotechSinovac Biotech · NCT02965404 · 270 enrolled · China
- Nov 28, 2016Phase 3 study in ChickenpoxSinovac Biotech · NCT02981836 · 5,997 enrolled · China
- Nov 28, 2017GC Biopharma’s first study: phase 3 study in Healthy ChildrenNew to GC BiopharmaGC Biopharma · NCT03375502 · 814 enrolled · Korea, Republic of
- Feb 14, 2019Phase 3 study in ChickenpoxMerck · NCT03843632 · 150 enrolled · Russian Federation
- Oct 14, 2021Phase 4 study in ChickenpoxSinovac Biotech · NCT05095701 · 703 planned · China
- Nov 22, 2021Phase 3 study in ChickenpoxSinovac Biotech · NCT05150392 · 1,193 enrolled · China
- Jul 12, 20222 phase 4 studies in ChickenpoxSinovac Biotech · NCT05470855, NCT05460429
- Dec 20, 2022Sinopharm’s first study: phase 3 study in ChickenpoxNew to SinopharmSinopharm · NCT05669625 · 12,440 enrolled · China
- Apr 20, 2023Phase 3 study in ChickenpoxSinopharm · NCT05839301 · 1,200 enrolled · China
- Mar 6, 2024Phase 3 study in ChickenpoxSinovac Biotech · NCT06314724 · 642 enrolled · Philippines
- Jun 26, 2024Phase 4 study in ChickenpoxSinovac Biotech · NCT06484686 · 414 planned · China
- Mar 2, 2025Phase 4 study in ChickenpoxSinovac Biotech · NCT06891872 · 720 planned · China
- May 15, 20252 phase 4 studiesSinovac Biotech · NCT06987942, NCT06994052
- Mar 11, 2026Phase 3 study in ChickenpoxSinovac Biotech · NCT07473427 · 300 planned · Vietnam
Ahead
- Dec 2028Primary completion: phase 4 study in ChickenpoxSinovac Biotech · NCT06484686
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
Studies
All 43 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07473427Chickenpox · Vietnam | 3 | Not yet recruiting | Sinovac Biotech | Aug 1, 2026 | 300 |
| NCT06994052VZV · China | 4 | Completed | Sinovac Biotech | Nov 30, 2024 | 412 |
| NCT06987942Chickenpox · China | 4 | Completed | Sinovac Biotech | Nov 15, 2024 | 899 |
| NCT06891872Chickenpox · China | 4 | Not yet recruiting | Sinovac Biotech | Dec 2025 | 720 |
| NCT06484686Chickenpox · China | 4 | By invitation | Sinovac Biotech | Dec 2028 | 414 |
| NCT06314724Chickenpox · Philippines | 3 | Completed | Sinovac Biotech | Sep 6, 2024 | 642 |
| NCT05839301Chickenpox · China | 3 | Active, not recruiting | Sinopharm | Jul 30, 2023 | 1,200 |
| NCT05669625Chickenpox · China | 3 | Active, not recruiting | Sinopharm | Apr 14, 2024 | 12,440 |
| NCT05470855Chickenpox · China | 4 | UNKNOWN | Sinovac Biotech | Nov 30, 2022 | 45,400 |
| NCT05460429Chickenpox · China | 4 | UNKNOWN | Sinovac Biotech | Mar 15, 2023 | 37,920 |
| NCT05150392Chickenpox · China | 3 | Completed | Sinovac Biotech | Aug 11, 2018 | 1,193 |
| NCT05095701Chickenpox · China | 4 | By invitation | Sinovac Biotech | Dec 19, 2021 | 703 |
| NCT03843632Chickenpox · Russian Federation | 3 | Completed | Merck | Jun 19, 2020 | 150 |
| NCT03375502Healthy Children · Korea, Republic of | 3 | Completed | GC Biopharma | Jan 29, 2019 | 814 |
| NCT02981836Chickenpox · China | 3 | Completed | Sinovac Biotech | Jun 2017 | 5,997 |
| NCT02965404Chickenpox · China | 1 | Completed | Sinovac Biotech | May 2016 | 270 |
| NCT02519855Herpes Zoster | 3 | Completed | Merck | Jan 26, 2016 | 882 |
| NCT01982409Chickenpox · China | 4 | UNKNOWN | Changchun Changsheng Life Science and Technology | Jan 2018 | 350 |
| NCT01556451Herpes Zoster | 4 | Completed | Merck | Oct 2012 | 180 |
| NCT01527370Herpes Zoster | 3 | Completed | Merck | Apr 9, 2013 | 250 |
| NCT01505647Herpes Zoster | 3 | Completed | Merck | Jul 2012 | 498 |
| NCT01391546Herpes Zoster | 3 | Completed | Merck | Oct 15, 2012 | 354 |
| NCT01385566Herpes Zoster | 1 | Completed | Merck | May 2013 | 223 |
| NCT01245751Herpes Zoster | 3 | Completed | Merck | Jul 2012 | 600 |
| NCT00822237Chickenpox | 3 | Completed | Merck | Oct 2009 | 598 |
| NCT00681031Herpes Zoster | 4 | Completed | Merck | Jun 25, 2008 | 96 |
| NCT00624819Streptococcal Infections · Poland | 3 | Completed | GlaxoSmithKline | Jun 2, 2008 | 524 |
| NCT00568334Chickenpox · Czechia, Hungary | 2 | Completed | GlaxoSmithKline | Mar 18, 2008 | 244 |
| NCT00561080Prevention of : Herpes-Zoster | 3 | Completed | Merck | Jun 3, 2009 | 759 |
| NCT00550745Herpes Zoster | 4 | Completed | Merck | Jan 2009 | 11,999 |
| NCT00546819Herpes Zoster | 2 | Completed | Merck | Aug 2010 | 309 |
| NCT00534248Herpes Zoster | 3 | Completed | Merck | Jan 2010 | 22,439 |
| NCT00496327Chickenpox | 3 | Completed | Merck | Oct 6, 2005 | 100 |
| NCT00444860Varicella Virus Infection | 3 | Completed | Merck | May 2007 | 150 |
| NCT00432731Chickenpox · France, Italy | 4 | Completed | Merck | Sep 2005 | 500 |
| NCT00432523Measles · France, Germany | 3 | Completed | Merck | Sep 5, 2005 | 752 |
| NCT00406211Rubella · Austria, Germany | 3 | Completed | GlaxoSmithKline | Dec 2004 | 398 |
| NCT00322231Herpes Zoster | 3 | Completed | Merck | Jul 2007 | 101 |
| NCT00289783Haemophilus Infections · United States, Australia, Mexico | 3 | Completed | GlaxoSmithKline | Aug 27, 2007 | 4,441 |
| NCT00231816Herpes Zoster | 3 | Completed | Merck | Mar 2006 | 763 |
| NCT00226499Chickenpox · Czechia, Greece, Italy and more | 3 | Completed | GlaxoSmithKline | Oct 12, 2006 | 5,803 |
| NCT00197015Hepatitis A · United States | 3 | Completed | GlaxoSmithKline | Jun 9, 2009 | 1,474 |
| NCT00109122Herpes Zoster | 2 | Completed | Merck | Feb 2003 | 180 |
How it is read
Names in the registry
- “Varicella Vaccine”, 4 entries
- “Investigational live attenuated varicella vaccine”, 4 entries
- “Zoster Vaccine, Live”, 3 entries
- “Varicella Virus Vaccine Live”, 2 entries
- “Live Attenuated Varicella Vaccine”, 2 entries
Conditions, from the studies’ own filings
- Chickenpox, 24 studies
- Herpes Zoster, 15 studies
- Meningococcal Infections, 1 study
- Measles, 1 study
- Streptococcal Infections, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.